Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Dynavax (DVAX) Q2 Revenue Jumps 29%


Dynavax Technologies (NASDAQ:DVAX), a biotechnology company focused on vaccines, released its results for the second quarter of 2025 on August 7, 2025. The company posted GAAP revenue of $95.4 million, sharply ahead of analyst expectations of $86.7 million, and GAAP diluted earnings per share (EPS) of $0.14 versus a $0.10 consensus estimate. This result marks significant year-over-year growth, with both GAAP revenue and earnings well above the same period in 2024. The quarter stood out for record sales of HEPLISAV-B, continued margin strength, and progress on multiple vaccine candidates. Overall, Dynavax delivered a strong quarter that beat internal and external forecasts, raised key product guidance, and continued to invest in its research pipeline.

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.

Dynavax Technologies is a biopharmaceutical company specializing in the development and commercialization of vaccines for infectious diseases. Its standout product is HEPLISAV-B, a two-dose adult hepatitis B vaccine approved in the U.S. European Union, and United Kingdom. The vaccine's two-dose schedule contrasts with traditional three-dose regimens, providing faster and stronger immune protection.

Continue reading


Source Fool.com

Dynavax Technologies Corp Stock

€8.51
-1.550%
We can see a decrease in the price for Dynavax Technologies Corp. Compared to yesterday it has lost -€0.134 (-1.550%).
With 2 Buy predictions and 1 Sell predictions the community is currently undecided on Dynavax Technologies Corp.
With a target price of 29 € there is potential for a 240.7% increase which would mean more than doubling the current price of 8.51 € for Dynavax Technologies Corp.
Like: 0
Share

Comments